Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Files An 8-K Other EventsItem 8.01.Other Events.
On December29, 2017, Atara Biotherapeutics, Inc. issued a press release titled “Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD),” a copy of which is attached hereto as Exhibit99.1 and is incorporated by reference herein.
Item 8.01.Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit Number |
Description |
| 99.1 | Press Release, dated December 29, 2017. |
Atara Biotherapeutics, Inc. ExhibitEX-99.1 2 d489039dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein- Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) – Pivotal studies to commence imminently – – Primary endpoint results and EU conditional marketing authorization submission expected in the first half of 2019 – – Company to host conference call and webcast today at 8:00 a.m. EST – SOUTH SAN FRANCISCO,…To view the full exhibit click here
About Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin.
